Predictive Biomarker for the Efficacy and Safety of the Combination of Chemotherapy and Tislelizumab in Non Small Cell Lung Cancer a Multicentre Prospective Clinical Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; Tislelizumab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms LungMark

06 Jun 2023 Status has been changed to completed, as Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
09 Aug 2022 Results (n=37) assessing activity and safety of neoadjuvant chemoimmunotherapy with tislelizumab, for resectable stage IIB-III NSCLC in Asian population, presented at the 2022 World Conference on Lung Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com